News Digest /
Income Statements /
Cannabis Bioscience Reports Q3 2025 Financials: Revenue Plummets but Losses Narrow
Cannabis Bioscience Reports Q3 2025 Financials: Revenue Plummets but Losses Narrow
StockInvest.us
04:05pm, Friday, May 09, 2025
Illustration by StockInvest.us
Cannabis Bioscience International Holdings, Inc. (PINK: CBIH) has reported its consolidated financial results for the quarter ended February 28, 2025, revealing both challenges and opportunities amidst ongoing operational changes.
Key Financial Highlights:
- Revenues: $14,931 (Q3 2025) vs. $36,411 (Q3 2024), indicating a significant decrease of 58.90% year-over-year.
- Gross Profit: Loss of $4,465 in Q3 2025 compared to a profit of $24,602 in Q3 2024.
- Operating Loss: Totaling $129,234 for Q3 2025 vs. $159,971 for Q3 2024, representing an improvement of 19.27% in operational efficiency.
- Net Loss: $181,243 in Q3 2025 compared to $209,192 in Q3 2024, indicating a reduction of 13.30% in overall losses.
- Assets: Total assets decreased to $14,886 from $57,162 one year prior.
- Cash Flow: Net cash used in operations was $185,315, improving from $304,943 in the same period last year.
- Working Capital Deficiency: Increased to $966,272 as of February 28, 2025.
- Debt Reduction: Forgiveness of $23,638 in debt recorded, improving financial position slightly.
- Common Stock: Increased shares outstanding to 10,931,749,347 from 10,431,749,347.
Positive Aspects:
- Reduction in operating loss from previous year highlights better cost management.
- Net losses decreased, suggesting improvements in overall financial health.
- Increased revenues year-to-date (nine months) to $268,066 from $172,979 in the same period previous year.
Negative Aspects:
- Sustained revenue decline in Q3 raises concerns about operational effectiveness, particularly in clinical trials.
- Significant working capital deficiency indicates potential liquidity issues.
- High operational expenditures leading to sustained losses amidst a low revenue generation scenario.
The company is actively seeking to expand operations and reduce expenses but faces substantial challenges in capitalizing on growth opportunities. The management continues to assess options for financing to ensure operations can proceed effectively.
About The Author
StockInvest.us
StockInvest.us is a stock market research tool that provides daily stock signals and technical analysis for over 25 000 tickers on 38 exchanges. The company was founded in 2016 in Vilnius, Lithuania.
Read Next in Income Statements
Trusted Broker
Start Your Journey With:
0% Commission Stock Trading
Follow Other Investors Strategy
Wide variety: Crypto, stocks, ETFs
Sign In